[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$vani Graphic](https://lunarcrush.com/gi/w:26/t:$vani.png) $vani

Weight-loss drugs are making headlines as new research reveals both benefits and risks. The market is expanding, but concerns about side effects and costs persist.

### About $vani
A topic related to the analysis of social media data and insights on the pharmaceutical industry, specifically focusing on the drug $vani.  

### Insights [#](/topic/$vani/insights)
- $vani mentions is at XXX which is XXX% higher than it's daily average.
- $vani Engagements hit a high of XXXXXX for the day
- $vani Engagements hit an all time of XXXXXX for the day

### Engagements: XXXXX [#](/topic/$vani/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$vani/c:line/m:interactions.svg)  
[Engagements 24-Hour Chart Data](/topic/$vani/time-series/interactions.tsv)  
**Current Value**: XXXXX  
**Daily Average**: XXXXX  
**1 Month**: XXXXXX +313%  
**1-Year High**: XXXXXX on 2025-07-13  
**1-Year Low**: X on 2025-04-27  

| Social Network | X     |
| -------------- | -     |
| Engagements    | XXXXX |
  

  
  
### Mentions: XXX [#](/topic/$vani/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$vani/c:line/m:posts_active.svg)  
[Mentions 24-Hour Chart Data](/topic/$vani/time-series/posts_active.tsv)  
**Current Value**: XXX  
**Daily Average**: XX  
**1 Week**: XXX -XX%  
**1 Month**: XXX +806%  
**1-Year High**: XXX on 2025-06-27  
**1-Year Low**: X on 2025-04-27  

| Social Network | X   |
| -------------- | -   |
| Mentions       | XXX |
  

  
  
### Creators: XX [#](/topic/$vani/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$vani/c:line/m:contributors_active.svg)  
[Creators 24-Hour Chart Data](/topic/$vani/time-series/contributors_active.tsv)  
XX unique social accounts have posts mentioning $vani in the last XX hours which is up XXXX% from XX in the previous XX hours
**Daily Average**: XX  
**1 Week**: XX -XX%  
**1 Month**: XXX +6,278%  
**1-Year High**: XXX on 2025-06-27  
**1-Year Low**: X on 2025-04-27  

The most influential creators that mention $vani in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) | X    | XXXXX     | XX    | XXXXX       |

[View More](/list/creators/$vani/100)
  
  
### Sentiment: XX% [#](/topic/$vani/sentiment)
---
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$vani/c:line/m:sentiment.svg)  
[Sentiment 24-Hour Chart Data](/topic/$vani/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Month**: XX% +23%  
**1-Year High**: XXX% on 2025-06-11  
**1-Year Low**: XX% on 2025-06-24  

**Most Supportive Themes**
- **Cardiometabolic Benefits:** (30%) Positive outcomes associated with GLP-1 receptor agonist therapy, including improved cardiometabolic outcomes, weight loss, and reduced risk of heart disease.
- **Hormonal and Sleep Benefits:** (15%) The potential of GLP-1 drugs to boost testosterone levels in men and improve sleep quality, leading to better weight loss results.
- **Market Expansion:** (10%) The expansion of Hims & Hers into Canada and the availability of Wegovy in Singapore, indicating market growth and accessibility.
- **New Research and Developments:** (5%) The emergence of new research and developments in GLP-1 therapies, including oral medications and gene editing approaches.
  
**Most Critical Themes**
- **GLP-1 Drug Risks:** (25%)  Concerns about the risks and side effects of GLP-1 drugs, including potential for optic nerve damage, gastroesophageal reflux disease, and mental health issues.
- **Cost and Economic Concerns:** (10%)  Criticism of the high cost and economic inefficiency of GLP-1 drugs, particularly in the context of Medicare coverage.
- **Unsupervised Use and Misleading Practices:** (5%)  Warnings against unsupervised use of weight-loss drugs and the potential for misleading advertising and pricing practices.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %  |
| ------- | -------- | -   | ------- | -   | -------- | -  |
| X       | XXXXX    | XX% | XXXXX   | XX% | XX       | X% |
|         |          |     |         |     |          |    |
| Total   | XXXXX    | XX% | XXXXX   | XX% | XX       | X% |
  


**Top assets mentioned**
In the posts about $vani in the last XX hours

[Hims & Hers Health, Inc. (HIMS)](/topic/$hims)
[GSK plc (GSK)](/topic/$gsk)
[Synthetify (SNY)](/topic/$sny)
[Eli Lilly and Company (LLY)](/topic/$lly)
[Novo-Nordisk (NVO)](/topic/$nvo)
[Eli Lilly and Company (LLY)](/topic/eli-lilly)
[AstraZeneca PLC (AZN)](/topic/$azn)
[Sanofi (SNY)](/topic/sanofi)
[GSK plc (GSK)](/topic/gsk-plc)
[Pfizer, Inc. (PFE)](/topic/$pfe)

**Top topics mentioned**
In the posts about $vani in the last XX hours

[stocks healthcare](/topic/stocks-healthcare), [stocks consumer defensive](/topic/stocks-consumer-defensive), [hims](/topic/hims), [manat](/topic/manat), [$hims](/topic/$hims), [$zldpf](/topic/$zldpf), [$rhhby](/topic/$rhhby), [$gsk](/topic/$gsk), [$sny](/topic/$sny), [$lly](/topic/$lly), [$nvo](/topic/$nvo), [eli lilly](/topic/eli-lilly), [$azn](/topic/$azn), [sanofi](/topic/sanofi), [gsk plc](/topic/gsk-plc), [$pfe](/topic/$pfe), [$vktx](/topic/$vktx), [hims hers](/topic/hims-hers), [stocks](/topic/stocks), [weight loss](/topic/weight-loss), [drugs](/topic/drugs), [coins defi](/topic/coins-defi), [stocks technology](/topic/stocks-technology), [stocks financial services](/topic/stocks-financial-services), [qqq](/topic/qqq), [spx](/topic/spx), [$qqq](/topic/$qqq), [$spx](/topic/$spx), [stocks bitcoin treasuries](/topic/stocks-bitcoin-treasuries), [$novcde](/topic/$novcde), [novo](/topic/novo), [coins solana ecosystem](/topic/coins-solana-ecosystem), [stocks industrials](/topic/stocks-industrials), [coins bsc](/topic/coins-bsc), [ozempic](/topic/ozempic), [mounjaro](/topic/mounjaro), [coins meme](/topic/coins-meme), [coins layer 1](/topic/coins-layer-1), [stocks consumer cyclical](/topic/stocks-consumer-cyclical), [coins exchange tokens](/topic/coins-exchange-tokens), [stocks crypto treasuries](/topic/stocks-crypto-treasuries), [coins pow](/topic/coins-pow), [coins made in usa](/topic/coins-made-in-usa), [stocks utilities](/topic/stocks-utilities), [coins gaming](/topic/coins-gaming), [coins arbitrum](/topic/coins-arbitrum), [coins brc20](/topic/coins-brc20), [investment](/topic/investment), [wegovy](/topic/wegovy), [coins layer 2](/topic/coins-layer-2), [canada](/topic/canada), [stocks real estate](/topic/stocks-real-estate), [$btcs](/topic/$btcs), [btcs btcs ordinals](/topic/btcs-btcs-ordinals), [btcs inc](/topic/btcs-inc), [gibraltar pound](/topic/gibraltar-pound), [$amgn](/topic/$amgn), [coins bitcoin ecosystem](/topic/coins-bitcoin-ecosystem), [$wint](/topic/$wint), [op](/topic/op), [$yhc](/topic/$yhc), [$game](/topic/$game), [$op](/topic/$op), [stocks banks](/topic/stocks-banks), [coins dao](/topic/coins-dao), [japan](/topic/japan), [saudi arabia](/topic/saudi-arabia), [coins ai agents](/topic/coins-ai-agents), [stocks basic materials](/topic/stocks-basic-materials), [$thto](/topic/$thto), [$adur](/topic/$adur), [$ccj](/topic/$ccj), [longterm](/topic/longterm), [singapore](/topic/singapore), [$prok](/topic/$prok), [$abve](/topic/$abve), [pfe](/topic/pfe), [srm](/topic/srm), [$aacg](/topic/$aacg), [$dlxy](/topic/$dlxy), [$hubc](/topic/$hubc), [$dtst](/topic/$dtst), [$nuwe](/topic/$nuwe), [$apm](/topic/$apm), [apm coin](/topic/apm-coin), [coins](/topic/coins), [$srm](/topic/$srm), [$crox](/topic/$crox), [$rytm](/topic/$rytm), [$wec](/topic/$wec), [coins ai](/topic/coins-ai), [wec energy group inc](/topic/wec-energy-group-inc), [$minm](/topic/$minm), [$tovx](/topic/$tovx), [$sowg](/topic/$sowg), [$fivn](/topic/$fivn), [coins base ecosystem](/topic/coins-base-ecosystem), [coins nft](/topic/coins-nft), [$sgi](/topic/$sgi), [integration](/topic/integration)

### Top Social Posts [#](/topic/$vani/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"I made $16307 this week with the help of @Yzq_hpp775. Their strategy is simple to understand and works great. Awesome 🚩🎌 $VLCN $XXII $ABVE $WINT $TRON $OPEN $BSLK $SRPT $TPCS $ZBAI $OPAD $BGLC $WIT $VANI $DCOMP $FVNNU $ARDT"  
[@AmandaBassc_](/creator/x/AmandaBassc_) on [X](/post/tweet/1945844979198562507) 2025-07-17 13:56:09 UTC X followers, XXX engagements


"🦉 Startups face direct liability as compounded GLP-1s bypass clinical trials lack consistency and trigger legal action over safety mislabeling and unfair competition. Investor trust is eroding fast. $NVO $LLY $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS #GLP1"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1945616354054185284) 2025-07-16 22:47:41 UTC 4947 followers, XXX engagements


"🦉 Insurers are now pulling back from covering compounded GLP-1 makers adding steep premiums and exclusions tied to non-FDA-approved products. Even valid claims are now at risk of denial. $NVO $LLY $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS #GLP1"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1945616351990604004) 2025-07-16 22:47:40 UTC 4947 followers, XXX engagements


"💼The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky Bet $NVO $LLY $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS #GLP1"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1945616349851496944) 2025-07-16 22:47:40 UTC 4947 followers, XXX engagements